IDEAYA Biosciences, Inc.
IDYA
Kedudukan dalam Saham
#4508
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Harga Saham
$35.54
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$3.43B
Perubahan (1 hari)
5.12%
Perubahan (1 tahun)
21.71%
Negara
US
Perdagangan IDEAYA Biosciences, Inc. (IDYA)
Kategori
Healthcare
Hasil untuk IDEAYA Biosciences, Inc. (IDYA)
Hasil pada Jun 2026 TTM: $234.13M
Menurut laporan kewangan terkini daripada IDEAYA Biosciences, Inc., hasil semasa syarikat (TTM) ialah $234.13M. Pada tahun 2023, syarikat memperoleh hasil sebanyak $23.39M penurunan berbanding hasil pada tahun 2022 iaitu $50.93M. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi IDEAYA Biosciences, Inc. dari 2017 hingga 2026
Hasil pada akhir setiap tahun
| Tahun | Hasil | Ubah |
|---|---|---|
| 2026 (TTM) | $234.13M | 3,244.67% |
| 2024 | $7.00M | -70.07% |
| 2023 | $23.39M | -54.08% |
| 2022 | $50.93M | 82.28% |
| 2021 | $27.94M | 43.01% |
| 2020 | $19.54M | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Hasil untuk syarikat atau pesaing serupa
| Syarikat | Hasil | Perbezaan Hasil | Negara |
|---|---|---|---|
| $12.62B | 5,292.07% |
US
|
|
| $2.23B | 851.62% |
US
|
|
| $15.74B | 6,624.70% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,471.80% |
NL
|
